Respiratory Syncytial Virus (RSV) Vaccine Clinical Study for Adults
Respiratory syncytial virus (RSV) is increasingly recognized as a significant cause of illness and death in elderly adults. The virus is highly contagious and causes symptoms similar to the common cold, but symptoms may be of increased severity and longer duration. An estimated 11,000 to 17,000 older adults die annually of RSV in the United States, and another 177,500 are hospitalized.
We are seeking volunteers ages 60 and older to participate in an RSV vaccine study. The study will help determine the safety and effectiveness of a single RSV injection compared to a placebo (no active medicine). The participants will be followed over a year by phone and 7 office visits to determine the occurrences of signs or symptoms of a respiratory infection.
Benefits to Participating:
- Compensation of at least $449 for completed study requirements.
- Study participants will be offered a flu vaccine at no cost.
- Participants will receive a medical exam upon initial visit at no cost.
- Two out of every three participants (or 66%) will receive an RSV vaccine.
- Participants will help advance science and medicine that protects their loved ones, their community, and future generations.
To Qualify you must be:
- 60 years of age or older.
- Able to complete study visits & able to use a smart phone. If you do not have a smart phone (iPhone, Android, or equivalent), a device will be provided to you.
- Generally healthy with no unstable medical conditions.